Summary
5.01 -0.07(-1.38%)09/06/2024
Vanda Pharmaceuticals Inc (VNDA)
Vanda Pharmaceuticals Inc (VNDA)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -1.57 | -5.20 | -5.65 | -19.84 | 27.81 | 14.12 | -63.08 | -48.24 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 5.01 | |
| Open | 5.08 | |
| High | 5.12 | |
| Low | 4.92 | |
| Volume | 409,702 | |
| Change | -0.08 | |
| Change % | -1.57 | |
| Avg Volume (20 Days) | 378,189 | |
| Volume/Avg Volume (20 Days) Ratio | 1.08 | |
| 52 Week Range | 3.30 - 6.75 | |
| Price vs 52 Week High | -25.78% | |
| Price vs 52 Week Low | 51.82% | |
| Range | -1.38 | |
| Gap Up/Down | -0.05 | |
Fundamentals | ||
| Market Capitalization (Mln) | 293 | |
| EBIDTA | 46,828,000 | |
| PE Ratio | 26.5667 | |
| PEG Ratio | -2.4200 | |
| WallStreet Target Price | 24.00 | |
| Book Value | 8.8550 | |
| Earnings Per Share | 0.6000 | |
| EPS Estimate Current Quarter | 0.1800 | |
| EPS Estimate Next Quarter | 0.1600 | |
| EPS Estimate Current Year | 0.5500 | |
| EPS Estimate Next Year | 0.9000 | |
| Diluted EPS (TTM) | 0.6000 | |
| Revenues | ||
| Profit Marging | 0.1277 | |
| Operating Marging (TTM) | 0.1639 | |
| Return on asset (TTM) | 0.0502 | |
| Return on equity (TTM) | 0.0734 | |
| Revenue TTM | 268,316,000 | |
| Revenue per share TTM | 4.8530 | |
| Quarterly Revenue Growth (YOY) | 0.1620 | |
| Quarterly Earnings Growth (YOY) | 0.2830 | |
| Gross Profit (TTM) | 224,804,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 26.5667 | |
| Forward PE | 30.3030 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 1.7855 | |
| Revenue Enterprise Value | 1.8172 | |
| EBITDA Enterprise Value | 10.4125 | |
| Shares | ||
| Shares Outstanding | 55,712,200 | |
| Shares Float | 46,852,871 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 2.72 | |
| Institutions (%) | 102.59 | |
09/04 17:13 EST - prnewswire.com
Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference
WASHINGTON , Sept. 4, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the H.C.
Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference
WASHINGTON , Sept. 4, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the H.C.
08/29 16:30 EST - prnewswire.com
Vanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare Conference
WASHINGTON , Aug. 29, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Wells Fargo 2024 Healthcare Conference in Boston on Friday, September 6, 2024. A corporate presentation is scheduled for 11:00 a.m.
Vanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare Conference
WASHINGTON , Aug. 29, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Wells Fargo 2024 Healthcare Conference in Boston on Friday, September 6, 2024. A corporate presentation is scheduled for 11:00 a.m.
08/08 14:19 EST - seekingalpha.com
Vanda Pharmaceuticals: I Believe That The Bidding War Is Not Over
Vanda Pharmaceuticals Inc. received and then refused two takeover bids that were well above current market prices. Vanda currently trades below net cash despite having significant revenue and operations. Vanda has disgruntled shareholders who may find creative ways to maximize shareholder value, despite a recent AGM failing to oust the unpopular Board of Directors and an existing poison pill.
Vanda Pharmaceuticals: I Believe That The Bidding War Is Not Over
Vanda Pharmaceuticals Inc. received and then refused two takeover bids that were well above current market prices. Vanda currently trades below net cash despite having significant revenue and operations. Vanda has disgruntled shareholders who may find creative ways to maximize shareholder value, despite a recent AGM failing to oust the unpopular Board of Directors and an existing poison pill.
08/02 13:14 EST - seekingalpha.com
Vanda Pharmaceuticals Inc. (VNDA) Q2 2024 Earnings Call Transcript
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Kevin Moran - Chief Financial Officer Mihael Polymeropoulos - President, Chief Executive Officer & Chairman of the Board Conference Call Participants Charles Duncan - Cantor Fitzgerald Andrew Tsai - Jefferies Operator Thank you for standing by. My name is Meg, and I will be your conference operator today.
Vanda Pharmaceuticals Inc. (VNDA) Q2 2024 Earnings Call Transcript
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA ) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Kevin Moran - Chief Financial Officer Mihael Polymeropoulos - President, Chief Executive Officer & Chairman of the Board Conference Call Participants Charles Duncan - Cantor Fitzgerald Andrew Tsai - Jefferies Operator Thank you for standing by. My name is Meg, and I will be your conference operator today.
07/31 16:01 EST - prnewswire.com
Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results
Revenues for Q2 2024 were $50.5 million, an increase of 6% compared to Q1 2024 and an increase of 10% compared to Q2 2023 Financial Guidance reinstated for Full Year 2024 Fanapt® approved for the acute treatment of bipolar I disorder; commercial launch initiated in Q3 2024 PONVORY® commercial launch in multiple sclerosis initiated in Q3 2024 Tradipitant NDA review for gastroparesis ongoing; PDUFA date of September 18, 2024 Positive results for tradipitant second Phase III motion sickness study results announced in May 2024; NDA expected to be submitted in Q4 2024 WASHINGTON , July 31, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2024. "2024 has been marked by the achievement of significant clinical development milestones and the expansion of our commercial organization to support the commercialization of Fanapt in bipolar disorder and Ponvory in multiple sclerosis," said Mihael H.
Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results
Revenues for Q2 2024 were $50.5 million, an increase of 6% compared to Q1 2024 and an increase of 10% compared to Q2 2023 Financial Guidance reinstated for Full Year 2024 Fanapt® approved for the acute treatment of bipolar I disorder; commercial launch initiated in Q3 2024 PONVORY® commercial launch in multiple sclerosis initiated in Q3 2024 Tradipitant NDA review for gastroparesis ongoing; PDUFA date of September 18, 2024 Positive results for tradipitant second Phase III motion sickness study results announced in May 2024; NDA expected to be submitted in Q4 2024 WASHINGTON , July 31, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2024. "2024 has been marked by the achievement of significant clinical development milestones and the expansion of our commercial organization to support the commercialization of Fanapt in bipolar disorder and Ponvory in multiple sclerosis," said Mihael H.
07/26 09:19 EST - prnewswire.com
Vanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024
Conference Call and Webcast to Follow WASHINGTON , July 26, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2024 on Wednesday, July 31, 2024, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, July 31, 2024, during which management will discuss the second quarter 2024 financial results and other corporate activities.
Vanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024
Conference Call and Webcast to Follow WASHINGTON , July 26, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2024 on Wednesday, July 31, 2024, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, July 31, 2024, during which management will discuss the second quarter 2024 financial results and other corporate activities.
07/01 08:01 EST - prnewswire.com
Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex
WASHINGTON , July 1, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. District Court for the District of Delaware (the "Court") denied the motions for judgment on the pleadings that were filed by Teva Pharmaceuticals USA, Inc. ("Teva") and Apotex Inc. and Apotex Corp. ("Apotex") and ordered that Vanda's HETLIOZ® patent lawsuit may proceed. Vanda brought this suit in December 2022, alleging patent infringement against Teva and Apotex (the "Defendants").
Federal Court Allows Vanda's HETLIOZ® Patent Lawsuit to Proceed against Teva and Apotex
WASHINGTON , July 1, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. District Court for the District of Delaware (the "Court") denied the motions for judgment on the pleadings that were filed by Teva Pharmaceuticals USA, Inc. ("Teva") and Apotex Inc. and Apotex Corp. ("Apotex") and ordered that Vanda's HETLIOZ® patent lawsuit may proceed. Vanda brought this suit in December 2022, alleging patent infringement against Teva and Apotex (the "Defendants").
06/26 18:27 EST - reuters.com
Future Pak withdraws offer to buy Vanda Pharmaceuticals
Contract manufacturer Future Pak said on Wednesday it has withdrawn its offer to acquire Vanda Pharmaceuticals , citing non-engagement from the U.S. drugmaker.
Future Pak withdraws offer to buy Vanda Pharmaceuticals
Contract manufacturer Future Pak said on Wednesday it has withdrawn its offer to acquire Vanda Pharmaceuticals , citing non-engagement from the U.S. drugmaker.
06/26 17:37 EST - businesswire.com
Future Pak Withdraws Proposal to Purchase Vanda Pharmaceuticals Inc.
WIXOM, Mich.--(BUSINESS WIRE)--Consistent with the position indicated in its June 13, 2024 letter to Vanda Pharmaceuticals (“Vanda”), Future Pak LLC and its affiliates ("Future Pak") today announced that it is withdrawing its offer to acquire the Company, effective immediately, and will focus on other strategic objectives. This action comes after a continued lack of engagement from Vanda and the receipt of Vanda's rejection of Future Pak's final proposal. About Future Pak Future Pak is a privat.
Future Pak Withdraws Proposal to Purchase Vanda Pharmaceuticals Inc.
WIXOM, Mich.--(BUSINESS WIRE)--Consistent with the position indicated in its June 13, 2024 letter to Vanda Pharmaceuticals (“Vanda”), Future Pak LLC and its affiliates ("Future Pak") today announced that it is withdrawing its offer to acquire the Company, effective immediately, and will focus on other strategic objectives. This action comes after a continued lack of engagement from Vanda and the receipt of Vanda's rejection of Future Pak's final proposal. About Future Pak Future Pak is a privat.
06/20 05:29 EST - benzinga.com
Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Thursday.
Vanda Pharmaceuticals And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Thursday.
06/19 21:40 EST - reuters.com
Vanda rejects Future Pak and Cycle Pharma's takeover offers
Vanda Pharmaceuticals said on Wednesday that it has rejected takeover offers from UK-based Cycle Pharmaceutical and a revised bid from contract manufacturer Future Pak, adding that both offers undervalue the U.S. drugmaker.
Vanda rejects Future Pak and Cycle Pharma's takeover offers
Vanda Pharmaceuticals said on Wednesday that it has rejected takeover offers from UK-based Cycle Pharmaceutical and a revised bid from contract manufacturer Future Pak, adding that both offers undervalue the U.S. drugmaker.
06/19 20:48 EST - prnewswire.com
Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its Shareholders
WASHINGTON , June 19, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Company's Board of Directors (the "Board"), following careful review and consultation with its independent financial and legal advisors, has determined that the unsolicited proposal from Cycle Group Holdings Ltd ("Cycle Group") to acquire Vanda for $8.00 per share in cash and the revised unsolicited proposal from Future Pak, LLC ("FP") to acquire Vanda for $8.50-$9.00 per share in cash plus certain Contingent Value Rights ("CVRs") both substantially undervalue Vanda and are not in the best interests of the Company and its shareholders. Accordingly, the Board has rejected the proposals.
Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its Shareholders
WASHINGTON , June 19, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Company's Board of Directors (the "Board"), following careful review and consultation with its independent financial and legal advisors, has determined that the unsolicited proposal from Cycle Group Holdings Ltd ("Cycle Group") to acquire Vanda for $8.00 per share in cash and the revised unsolicited proposal from Future Pak, LLC ("FP") to acquire Vanda for $8.50-$9.00 per share in cash plus certain Contingent Value Rights ("CVRs") both substantially undervalue Vanda and are not in the best interests of the Company and its shareholders. Accordingly, the Board has rejected the proposals.
06/17 21:59 EST - seekingalpha.com
Vanda Pharmaceuticals: Undervalued With Promising Pipeline And Acquisition Interest
Vanda Pharmaceuticals' portfolio includes FDA-approved Hetlioz for sleep disorders, Fanapt for schizophrenia and bipolar I disorder, and Ponvory for multiple sclerosis. VNDA's upcoming pipeline features milsaperidone and tradipitant, with promising Phase III trials for new indications and long-acting injectables. Acquisition offers from Future Pak and Cycle Pharmaceuticals highlight VNDA's undervaluation and strategic value.
Vanda Pharmaceuticals: Undervalued With Promising Pipeline And Acquisition Interest
Vanda Pharmaceuticals' portfolio includes FDA-approved Hetlioz for sleep disorders, Fanapt for schizophrenia and bipolar I disorder, and Ponvory for multiple sclerosis. VNDA's upcoming pipeline features milsaperidone and tradipitant, with promising Phase III trials for new indications and long-acting injectables. Acquisition offers from Future Pak and Cycle Pharmaceuticals highlight VNDA's undervaluation and strategic value.
06/13 21:00 EST - globenewswire.com
Global Bipolar Disorder Market Size To Exceed USD 6.47 Billion By 2033 | CAGR Of 1.98%
The Global Bipolar Disorder Market Size was Valued at USD 5.32 Billion in 2023, the Worldwide Bipolar Disorder Market Size is Expected to Reach USD 6.47 Billion by 2033, according to a research report published by Spherical Insights & Consulting. Companies covered: Bristol Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, H. Lundbeck A/S, Janssen Pharmaceuticals Inc., Otsuka Holdings Co. Ltd., Pfizer Inc., Sunovion Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Abbott Laboratories, Novartis International AG, Alkermes plc, AbbVie Inc., Merck & Co. Inc., Mylan N.V., Neurocrine Biosciences Inc., Vanda Pharmaceuticals Inc., and Key Others Key Vendors. The Global Bipolar Disorder Market Size was Valued at USD 5.32 Billion in 2023, the Worldwide Bipolar Disorder Market Size is Expected to Reach USD 6.47 Billion by 2033, according to a research report published by Spherical Insights & Consulting. Companies covered: Bristol Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, H. Lundbeck A/S, Janssen Pharmaceuticals Inc., Otsuka Holdings Co. Ltd., Pfizer Inc., Sunovion Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Abbott Laboratories, Novartis International AG, Alkermes plc, AbbVie Inc., Merck & Co. Inc., Mylan N.V., Neurocrine Biosciences Inc., Vanda Pharmaceuticals Inc., and Key Others Key Vendors.
Global Bipolar Disorder Market Size To Exceed USD 6.47 Billion By 2033 | CAGR Of 1.98%
The Global Bipolar Disorder Market Size was Valued at USD 5.32 Billion in 2023, the Worldwide Bipolar Disorder Market Size is Expected to Reach USD 6.47 Billion by 2033, according to a research report published by Spherical Insights & Consulting. Companies covered: Bristol Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, H. Lundbeck A/S, Janssen Pharmaceuticals Inc., Otsuka Holdings Co. Ltd., Pfizer Inc., Sunovion Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Abbott Laboratories, Novartis International AG, Alkermes plc, AbbVie Inc., Merck & Co. Inc., Mylan N.V., Neurocrine Biosciences Inc., Vanda Pharmaceuticals Inc., and Key Others Key Vendors. The Global Bipolar Disorder Market Size was Valued at USD 5.32 Billion in 2023, the Worldwide Bipolar Disorder Market Size is Expected to Reach USD 6.47 Billion by 2033, according to a research report published by Spherical Insights & Consulting. Companies covered: Bristol Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, H. Lundbeck A/S, Janssen Pharmaceuticals Inc., Otsuka Holdings Co. Ltd., Pfizer Inc., Sunovion Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Abbott Laboratories, Novartis International AG, Alkermes plc, AbbVie Inc., Merck & Co. Inc., Mylan N.V., Neurocrine Biosciences Inc., Vanda Pharmaceuticals Inc., and Key Others Key Vendors.
06/13 10:02 EST - prnewswire.com
Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak
No Shareholder Action Required at This Time WASHINGTON , June 13, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that it has received a revised unsolicited proposal from Future Pak, LLC ("FP") to acquire Vanda for $8.50-$9.00 per share in cash plus certain Contingent Value Rights. Consistent with its fiduciary duties, and in consultation with its financial and legal advisors, Vanda's Board will carefully review and evaluate the revised, non-binding proposal to determine the course of action that it believes is in the best interests of the Company and its shareholders.
Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak
No Shareholder Action Required at This Time WASHINGTON , June 13, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that it has received a revised unsolicited proposal from Future Pak, LLC ("FP") to acquire Vanda for $8.50-$9.00 per share in cash plus certain Contingent Value Rights. Consistent with its fiduciary duties, and in consultation with its financial and legal advisors, Vanda's Board will carefully review and evaluate the revised, non-binding proposal to determine the course of action that it believes is in the best interests of the Company and its shareholders.
06/13 08:36 EST - reuters.com
Future Pak raises cash portion of buyout offer for Vanda
Contract manufacturer Future Pak said on Thursday it has raised the cash portion of its buyout offer as part of a final attempt to acquire Vanda Pharmaceuticals.
Future Pak raises cash portion of buyout offer for Vanda
Contract manufacturer Future Pak said on Thursday it has raised the cash portion of its buyout offer as part of a final attempt to acquire Vanda Pharmaceuticals.
06/13 08:15 EST - businesswire.com
Future Pak Issues Enhanced and Final Proposal to Acquire Vanda Pharmaceuticals Inc.
WIXOM, Mich.--(BUSINESS WIRE)--Future Pak, LLC and its affiliates ("Future Pak") today announced that it has submitted a final attempt to engage with Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") in a good faith effort to acquire all outstanding shares of Vanda (the “Transaction”). Following the offer announced by Cycle Pharmaceuticals Ltd on June 6, 2024 to acquire Vanda as well as Future Pak's improved offer, it is clear that Vanda's Board should conduct a process to explore strategic.
Future Pak Issues Enhanced and Final Proposal to Acquire Vanda Pharmaceuticals Inc.
WIXOM, Mich.--(BUSINESS WIRE)--Future Pak, LLC and its affiliates ("Future Pak") today announced that it has submitted a final attempt to engage with Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") in a good faith effort to acquire all outstanding shares of Vanda (the “Transaction”). Following the offer announced by Cycle Pharmaceuticals Ltd on June 6, 2024 to acquire Vanda as well as Future Pak's improved offer, it is clear that Vanda's Board should conduct a process to explore strategic.
06/10 08:17 EST - businesswire.com
CIONIC Unveils Three New Centers of Excellence on the East Coast to Aid Patient Mobility Through the Use of FDA-Cleared Bionic Clothing and Neuromodulation
SAN FRANCISCO--(BUSINESS WIRE)-- #assistivetechnology--CIONIC Unveils Three New Centers of Excellence to Aid Patient Mobility Through the Use of FDA-Cleared Bionic Clothing and Neuromodulation.
CIONIC Unveils Three New Centers of Excellence on the East Coast to Aid Patient Mobility Through the Use of FDA-Cleared Bionic Clothing and Neuromodulation
SAN FRANCISCO--(BUSINESS WIRE)-- #assistivetechnology--CIONIC Unveils Three New Centers of Excellence to Aid Patient Mobility Through the Use of FDA-Cleared Bionic Clothing and Neuromodulation.
06/10 08:14 EST - businesswire.com
Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) concerning the Company and its directors' and officers' possible violations of state laws. If you own Vanda Pharmaceuticals stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Tom Kennedy, of GPM, 230 Park Avenue, Suite 358, New York,.
Glancy Prongay & Murray LLP Announces Investigation of Vanda Pharmaceuticals Inc.
NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) concerning the Company and its directors' and officers' possible violations of state laws. If you own Vanda Pharmaceuticals stock, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Tom Kennedy, of GPM, 230 Park Avenue, Suite 358, New York,.
06/07 07:06 EST - zacks.com
Vanda (VNDA) Surges 24.2%: Is This an Indication of Further Gains?
Vanda (VNDA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Vanda (VNDA) Surges 24.2%: Is This an Indication of Further Gains?
Vanda (VNDA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.